Quest Diagnostics Raises FY Outlook on Higher 1Q Sales, Profit

Dow Jones04-21

By Katherine Hamilton

Quest Diagnostics raised its full-year outlook after posting higher profit and sales in the first quarter.

The medical testing company on Tuesday posted a profit of $252 million, or $2.24 a share, in the quarter ended March 31, compared with $220 million, or $1.94 a share, a year earlier.

Stripping out certain one-time items, adjusted per-share earnings were $2.50, ahead of the $2.37 anticipated by analysts, according to FactSet.

Revenue rose 9.2% to $2.90 billion. Analysts surveyed by FactSet forecast revenue of $2.83 billion.

Quest had higher sales across advanced diagnostics, including its AD-Detect blood tests for Alzheimer's disease and in several clinical areas of advanced cardiometabolic and endocrine disease, it said.

Quest also raised its full-year outlook. It now expects revenue to be $11.78 billion to $11.90 billion, up from a prior range of $11.70 billion to $11.82 billion. It projects adjusted earnings per share will be $10.63 to $10.83, up from $10.50 to $10.70.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

April 21, 2026 07:01 ET (11:01 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2629003388?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-21 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629003388","market":"other","top_or_hot":-1,"title":"Quest Diagnostics Raises FY Outlook on Higher 1Q Sales, Profit","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Quest Diagnostics raised its full-year outlook after posting higher profit and sales in the first quarter. \n</p>\n<p>\n  The medical testing company on Tuesday posted a profit of $252 million, or $2.24 a share, in the quarter ended March 31, compared with $220 million, or $1.94 a share, a year earlier. \n</p>\n<p>\n  Stripping out certain one-time items, adjusted per-share earnings were $2.50, ahead of the $2.37 anticipated by analysts, according to FactSet. \n</p>\n<p>\n  Revenue rose 9.2% to $2.90 billion. Analysts surveyed by FactSet forecast revenue of $2.83 billion. \n</p>\n<p>\n  Quest had higher sales across advanced diagnostics, including its AD-Detect blood tests for Alzheimer's disease and in several clinical areas of advanced cardiometabolic and endocrine disease, it said. \n</p>\n<p>\n  Quest also raised its full-year outlook. It now expects revenue to be $11.78 billion to $11.90 billion, up from a prior range of $11.70 billion to $11.82 billion. It projects adjusted earnings per share will be $10.63 to $10.83, up from $10.50 to $10.70. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 21, 2026 07:01 ET (11:01 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Quest Diagnostics Raises FY Outlook on Higher 1Q Sales, Profit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQuest Diagnostics Raises FY Outlook on Higher 1Q Sales, Profit\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-21 19:01</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Quest Diagnostics raised its full-year outlook after posting higher profit and sales in the first quarter. \n</p>\n<p>\n  The medical testing company on Tuesday posted a profit of $252 million, or $2.24 a share, in the quarter ended March 31, compared with $220 million, or $1.94 a share, a year earlier. \n</p>\n<p>\n  Stripping out certain one-time items, adjusted per-share earnings were $2.50, ahead of the $2.37 anticipated by analysts, according to FactSet. \n</p>\n<p>\n  Revenue rose 9.2% to $2.90 billion. Analysts surveyed by FactSet forecast revenue of $2.83 billion. \n</p>\n<p>\n  Quest had higher sales across advanced diagnostics, including its AD-Detect blood tests for Alzheimer's disease and in several clinical areas of advanced cardiometabolic and endocrine disease, it said. \n</p>\n<p>\n  Quest also raised its full-year outlook. It now expects revenue to be $11.78 billion to $11.90 billion, up from a prior range of $11.70 billion to $11.82 billion. It projects adjusted earnings per share will be $10.63 to $10.83, up from $10.50 to $10.70. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 21, 2026 07:01 ET (11:01 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DGX","symbol_name":"奎斯特诊疗","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2629003388","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2629003388","pubTimestamp":1776769260,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Quest Diagnostics raised its full-year outlook after posting higher profit and sales in the first quarter.The medical testing company on Tuesday posted a profit of $252 million, or $2.24 a share, in the quarter ended March 31, compared with $220 million, or $1.94 a share, a year earlier.Stripping out certain one-time items, adjusted per-share earnings were $2.50, ahead of the $2.37 anticipated by analysts, according to FactSet.Revenue rose 9.2% to $2.90 billion. Analysts surveyed by FactSet forecast revenue of $2.83 billion.Quest had higher sales across advanced diagnostics, including its AD-Detect blood tests for Alzheimer's disease and in several clinical areas of advanced cardiometabolic and endocrine disease, it said.Quest also raised its full-year outlook. It now expects revenue to be $11.78 billion to $11.90 billion, up from a prior range of $11.70 billion to $11.82 billion. It projects adjusted earnings per share will be $10.63 to $10.83, up from $10.50 to $10.70.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"DGX":"奎斯特诊疗"},"translate_title":"Quest Diagnostics因第一季度销售额和利润增加而上调财年前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DGX":1.5},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Quest Diagnostics raised its full-year outlook after posting higher profit and sales in the first quarter. \n\n\n  The medical testing company on Tuesday posted a profit of $252 million, or $2.24 a share, in the quarter ended March 31, compared with $220 million, or $1.94 a share, a year earlier. \n\n\n  Stripping out certain one-time items, adjusted per-share earnings were $2.50, ahead of the $2.37 anticipated by analysts, according to FactSet. \n\n\n  Revenue rose 9.2% to $2.90 billion. Analysts surveyed by FactSet forecast revenue of $2.83 billion. \n\n\n  Quest had higher sales across advanced diagnostics, including its AD-Detect blood tests for Alzheimer's disease and in several clinical areas of advanced cardiometabolic and endocrine disease, it said. \n\n\n  Quest also raised its full-year outlook. It now expects revenue to be $11.78 billion to $11.90 billion, up from a prior range of $11.70 billion to $11.82 billion. It projects adjusted earnings per share will be $10.63 to $10.83, up from $10.50 to $10.70. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 21, 2026 07:01 ET (11:01 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2629003388","isCrawlerRequest":true}